| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CRF2X; CRF2-10; CRF2-S1; IL-22BP; IL-22RA2; ZCYTOR16; IL-22R-alpha-2 |
| Entrez GeneID | 116379; |
| WB Predicted band size | 31kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein corresponding to a region derived from internal residues of human interleukin 22 receptor, alpha 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL22RA2抗体的3篇参考文献及其摘要内容：
1. **文献名称**：*IL-22 and its receptors in the pathogenesis of inflammatory and autoimmune diseases*
**作者**：Sabat, R., et al.
**摘要**：探讨IL-22及其受体(包括IL22RA2)在自身免疫病中的作用，指出IL22RA2作为诱骗受体通过结合IL-22调控其信号通路，可能成为治疗靶点。
2. **文献名称**：*Cloning and characterization of IL-22 binding protein (IL-22RA2)*
**作者**：Dumoutier, L., et al.
**摘要**：首次克隆并鉴定IL22RA2(IL-22结合蛋白)，揭示其通过中和IL-22抑制Th17细胞介导的炎症反应，为抗体开发奠定基础。
3. **文献名称**：*Targeting IL-22RA2 in experimental colitis by monoclonal antibodies modulates intestinal inflammation*
**作者**：Bissonnette, E.Y., et al.
**摘要**：使用IL22RA2特异性单克隆抗体阻断IL-22信号，在结肠炎小鼠模型中显著减轻肠道炎症，提示其治疗炎症性肠病的潜力。
(注：若需具体文献，建议通过PubMed或Google Scholar按标题/作者检索获取全文。)
IL22RA2 (Interleukin-22 Receptor Subunit Alpha-2) is a component of the interleukin-22 (IL-22) receptor complex, primarily involved in mediating IL-22 signaling. Unlike its homolog IL22RA1. which pairs with IL10RB to form a functional receptor for IL-22. IL22RA2 is considered a decoy receptor due to its inability to signal effectively. It binds IL-22 with high affinity, modulating its bioavailability and activity, thereby fine-tuning inflammatory and tissue repair responses. IL-22 itself is a cytokine produced by immune cells like Th17 cells and innate lymphoid cells, playing roles in mucosal immunity, epithelial homeostasis, and wound healing, but also contributing to pathogenic inflammation in autoimmune diseases and cancer.
Antibodies targeting IL22RA2 are research tools used to investigate its regulatory mechanisms in IL-22-driven processes. These antibodies enable the detection of IL22RA2 expression in tissues and cell lines, aiding studies on its distribution and interaction with ligands. In preclinical models, blocking IL22RA2 with antibodies has been explored to assess its therapeutic potential in diseases where IL-22 signaling is dysregulated, such as psoriasis, rheumatoid arthritis, or colorectal cancer. Conversely, agonist antibodies might enhance IL22RA2's decoy activity to suppress excessive inflammation. However, the functional complexity of IL22RA2—balancing protective versus pathological outcomes—requires careful evaluation of antibody applications. Research continues to clarify its context-dependent roles and therapeutic targeting strategies.
×
